Perspectives and Challenges on the Potential Use of Exosomes in Bioartificial Pancreas Engineering.

Ann Biomed Eng

Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USA.

Published: October 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Exosomes are enclosed within a single outer membrane and exemplify a specific subtype of secreted vesicles. Exosomes transfer signalling molecules, including microRNAs (miRNAs), messenger RNA (mRNA), fatty acids, proteins, and growth factors, making them a promising therapeutic tool. In routine bioartificial pancreas fabrication, cells are immobilized in polymeric hydrogels lacking attachment capability for cells and other biological cues. In this opinion article, we will discuss the potential role that exosomes and their specific biofactors may play to improve and sustain the function of this bioartificial construct. We will particularly discuss the challenges associated with their isolation and characterization. Since stem cells are an attractive source of exosomes, we will present the advantages of using exosomes in place of stem cells in medical devices including the bioartificial pancreas. We will provide literature evidence of active biofactors in exosomes to support their incorporation in the matrix of encapsulated islets. This will include their potential beneficial effect on hypoxic injury to encapsulated islets. In summary, we propose that the biofactors contained in secreted exosomes have significant potential to enhance the performance of islets encapsulated in polymeric material hydrogels with perm-selective properties to provide immunoisolation for islet transplants as an insulin delivery platform in diabetes.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10439-022-03004-0DOI Listing

Publication Analysis

Top Keywords

bioartificial pancreas
12
exosomes
8
will discuss
8
stem cells
8
encapsulated islets
8
will
5
perspectives challenges
4
potential
4
challenges potential
4
potential exosomes
4

Similar Publications

Allogeneic cell transplantation such as beta-cell replacement for treatment of type 1 diabetes (T1D) is constrained by poor graft survival and functionality, immune rejection, and the lack of scalable biomanufacturing processes. Here, we engineered functional human islet constructs that replicate the physiomimetic human pancreatic microenvironment by employing a clinically-scalable 3D bioprinting system. To support human islet viability and function, we developed alginate-based bioinks incorporating human pancreatic decellularized extracellular matrix (dECM).

View Article and Find Full Text PDF

Background: Type 1 diabetes mellitus (T1D) is an autoimmune disease marked by the destruction of pancreatic β cells, necessitating lifelong management. Current therapies, such as insulin injections and pancreas transplants, are effective but impose significant burdens, driving the need for innovative solutions. Among these, the bioartificial pancreas (BAP) stands out as a promising approach.

View Article and Find Full Text PDF

Millions of individuals worldwide suffer from a chronic metabolic disorder, diabetes, defined as a reduction in insulin production or sensitivity, which raises blood glucose levels, weakens the immune system, and results in irregularities in the metabolism of carbohydrates, fats, and proteins. Therefore, there is still a high demand for non-invasive ways to administer insulin and other antidiabetics to treat diabetes and suitable therapeutics for wound healing. This generates a need for novel biomaterials that effectively use diabetes-associated therapy.

View Article and Find Full Text PDF

Type 1 diabetes mellitus (T1DM) involves the destruction of pancreatic β-cells, requiring ongoing insulin therapy. A promising alternative for management is pancreatic islet transplantation, or the bioartificial pancreas. Here, we examine the primary implantation sites for the bioartificial pancreas, highlighting their anatomical, physical, and immunological characteristics in the context of T1DM treatment.

View Article and Find Full Text PDF

Mesoporous Semi-Permeable Flexible Polyurethane Membranes: Advancing Bioartificial Pancreas Design for Type 1 Diabetes Treatment.

Macromol Rapid Commun

July 2025

Institut de Chimie et Procédés pour l'Energie, l'Environnement et la Santé, ICPEES UMR 7515, CNRS, Université de Strasbourg, Ecole Européenne de Chimie, Polymères et Matériaux, 25 rue Becquerel, Strasbourg, Cedex 267087, France.

This study reports the development of elastomeric mesoporous polyurethane (PU) membranes for bioartificial pancreas applications in type 1 diabetes treatment. The membranes are designed to exhibit semi-permeable properties, enabling insulin diffusion while restricting larger immune molecules, such as immunoglobulin G (IgG). Although electrospinning is a widely used technique for fabricating porous membranes for controlled drug release, it typically results in an average pore size on the order of few micrometers, which is two orders of magnitude larger than the mesoporous scale required.

View Article and Find Full Text PDF